DOI: http://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20182730

A feedback survey on the clinical performance and acceptability of levonorgestrel releasing intrauterine system (EMILY®) during two years of usage

Manoj G., Amrutha C., Rajmohan G., Sunil Bhaskar, Rajeev A., Abi Santhosh Aprem

Abstract


Background: Objective of the study was to evaluate the long term clinical performance and acceptability of levenorgestrel releasing intrauterine system (LNG-IUS), ‘Emily’, for the treatment of abnormal uterine bleeding (AUB).

Methods: A two year feed back survey was carried out by telephonic conversation and the data obtained was fed in to the house web application system in the respective Emily users. Subjective perceptions were verbally assured based on a questionnaire framed on the quality of the life led by the Emily users.  

Results: The treatment resulted in a significant reduction in the menstrual bleeding of 102 patients who completed the two year study. The mean bleeding score and SD 18.79 (13.36) in first year falls to 10.76 (12.40) in second year. 78 (76.47%) users were very satisfied with the product usage.

Conclusions: Use of ‘Emily’ LNG-IUS resulted in significant reduction of menstrual bleeding in women with AUB in two years and most of the users were very satisfied with the product.


Keywords


LNG-IUS, Emily, AUB

Full Text:

PDF

References


Cooper JM. Contemporary management of abnormal uterine bleeding. Preface. Obstet Gynaecol Clinics North Am. 2000;27:11–3.

Matteson KA, Abed H, Wheeler TL, Sung VW, Rahn DD, Schaffer JI, et al. A systematic review comparing hysterectomy with less-invasive treatments for abnormal uterine bleeding. J Minimal Invasive Gynaecol. 2012;19:13–28.

Shawki O, Wahba A, Magon N. Abnormal uterine bleeding in midlife: The role of levonorgestrel intrauterine system. Mid-life Health. 2013;4:36–9.

Singh S, Best C, Dunn S, Leyland N, Wolfman WL. Clinical Practice—Gynaecology Committee et al. Abnormal uterine bleeding in premenopausal women. J Obestet Gynaecol Canada. 2013;35:473–9.

Mi-La K, Seok JS. Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases. Obstet Gynecol Sci. 2013;56:67–75.

Nelson AL. LNG-IUS 12: a 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years. Expert Opinion Drug Deliv. 2017;14:1131-40.

Dominick S, Hickey M, Chin J, Su HI. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database System Rev. 2015;9:12.

Gopimohan R, Chandran A, Jacob J, Bhaskar S, Aravindhakshan R, Aprem AS. A clinical study assessing the efficacy of a new variant of the levonorgestrel intrauterine system for abnormal uterine bleeding. Int J Gynecology Obstet. 2015;129:114-7.

Shaw V, Vandal AC, Coomarasamy C, Ekeroma AJ. The effectiveness of the levonorgestrel intrauterine system in obese women with heavy menstrual bleeding. Australian New Zealand J Obstet Gynaecol. 2016;56:619-23.

Eralil GJ. The Effectiveness of Levonorgestrel-Releasing Intrauterine System in the Treatment of Heavy Menstrual Bleeding. J Obstet Gynecol India. 2016;66:505-12.

Paula HB, Jeffrey TJ. Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS. Int J Women's Health. 2009;1:45–58.

Senol T, Kahramanoglu I, Dogan Y, Baktiroglu M, Karateke A, Suer N. Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma. Clinical experimental obstet gynecol. 2015;42:224-7.

Awasthi D, Kulshrestha V, Agarwal N. Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma. Int J Gynecol Obstet. 2012;116:35–8.

Tariq N, Ayub R, Jaffery T, Rahim F, Naseem F, Kamal M. Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraception. J College Physicians Surgeons Pakistan. 2011;21:210-3.

Palmara V, Sturlese E, Villari D, Giacobbe V, Retto A, Santoro G. Levonorgestrel-releasing intrauterine device in the treatment of abnormal uterine bleeding: a 6- and 12-month morphological and clinical follow-up. Australian New Zealand J Obstet Gynaecol. 2013;53:381–5.